FDA Moves Dissolvable Antibiotic Bone Filler to Class II
Published Date: 6/5/2026
Rule
Summary
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Easier FDA Path for Device Makers
The FDA has classified a resorbable calcium salt bone void filler with a single approved aminoglycoside antibacterial as Class II, effective June 5, 2026 (classification applicable May 17, 2022). That means the product can serve as a predicate device so other makers can use the less-burdensome 510(k) premarket notification pathway instead of automatic Class III premarket approval, which the FDA says will reduce regulatory burdens and help speed patient access.
More Patient Access to Bone Filler
You (patients) may get earlier access to a resorbable bone void filler intended to reduce recurrence of chronic osteomyelitis of long bones because FDA placed this product into Class II with special controls (order effective June 5, 2026; classification applicable May 17, 2022). The rule also lists required safety measures — such as clinical and animal testing, labeling about risks (including antimicrobial resistance and systemic adverse effects), and sterility and stability data — to provide reasonable assurance of safety and effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18432, Medical Devices; Cardiovascular Devices; Classification of the Temperature Regulation Device for Esophageal Protection During Cardiac Ablation Procedures
The Food and Drug Administration (FDA) is classifying the temperature regulation device for esophageal protection during cardiac ablation procedures into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the temperature regulation device for esophageal protection during cardiac ablation procedures. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18426, Medical Devices; General Hospital and Personal Use Devices; Classification of the Whole Room Microbial Reduction Device
The Food and Drug Administration (FDA) is classifying the whole room microbial reduction device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the whole room microbial reduction device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18433, Medical Devices; Cardiovascular Devices; Classification of the Mechanical Deviation Device for Esophageal Protection During Cardiac Ablation Procedures
The FDA is officially classifying a new device that protects the esophagus during heart procedures as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get access to this cool innovation faster by cutting down on red tape. The new classification took effect on September 10, 2026, but has been in place since September 6, 2023, making it easier and potentially cheaper for makers to bring this device to market.
Previous / Next Documents
Previous: 2026-11307, Amendment of Class E Airspace; Springfield, KY
The FAA is updating the Class E airspace around Lebanon Springfield Airport in Springfield, KY, to match new flight procedures and correct the airport’s name and location info. This change helps pilots fly safely using instruments and kicks in on September 3, 2026. No extra costs for anyone—just smoother skies and clearer rules!
Next: 2026-11311, Special Local Regulation; Genesee River, Rochester, NY
On June 20, 2026, the Coast Guard will temporarily block off part of the Genesee River in Rochester, NY, for a thrilling Harborfest Water Ski Show. Boats and people can’t enter the area from 11:45 a.m. to 5:30 p.m. unless they get special permission. This keeps everyone safe during the high-speed water fun without costing anyone a dime!